BioNexus Gene Lab
BGLC
2 hedge funds and large institutions have $122K invested in BioNexus Gene Lab in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
315% more capital invested
Capital invested by funds: $29.4K → $122K (+$92.5K)
100% more funds holding
Funds holding: 1 → 2 (+1)
0.71% more ownership
Funds ownership: 0.53% → 1.24% (+0.71%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$81.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$10.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DS
1
DRW Securities
Chicago,
Illinois
| $80.1K | +$81.5K | +14,651 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $41.7K | -$10.8K | -1,936 | -20% |
|
BGLC Hedge Fund Activity: Q3 2025 in Review
2 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in BioNexus Gene Lab (BGLC) for Q3 2025, worth a combined $122K — up 315% from $29.4K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BGLC positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was DRW Securities, opening a new position worth an estimated $81.5K. The largest seller was UBS Group, cutting an estimated $10.8K.
- 2 institutional investors held BioNexus Gene Lab (BGLC) as of Q3 2025, up from 1 in Q2 2025.
- Funds reported $122K of BioNexus Gene Lab stock for Q3 2025, up 315% quarter-over-quarter.
- 1 fund opened new BioNexus Gene Lab positions in Q3 2025 and 0 closed out, a net change of +1 holder.
- The largest BioNexus Gene Lab buyer in Q3 2025 was DRW Securities, an estimated $81.5K added.
- The largest BioNexus Gene Lab seller in Q3 2025 was UBS Group, an estimated $10.8K sold.
Based on aggregated 13F filings for Q3 2025.